PepGen Inc. (PEPG)
NASDAQ
Market Cap
$78.56M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
21 of 951
Rank in Industry
16 of 544
Largest Insider Buys in Sector
PEPG Stock Price History Chart
PEPG Stock Performance
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Insider Activity of PepGen Inc.
Over the last 12 months, insiders at PepGen Inc. have bought $27.21M and sold $1.04M worth of PepGen Inc. stock.
On average, over the past 5 years, insiders at PepGen Inc. have bought $14.44M and sold $827,860 worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $816.38M.
The last purchase of 2,557,593 shares for transaction amount of $27.21M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑02‑09.
List of Insider Buy and Sell Transactions, PepGen Inc.
| 2024-07-25 | Sale | Chief Medical Officer | 7,571 0.0234% | $18.06 | $136,741 | -52.00% | ||
| 2024-07-24 | Sale | Chief Medical Officer | 201 0.0006% | $18.01 | $3,619 | 0.00% | ||
| 2024-07-18 | Sale | Chief Medical Officer | 12,625 0.0427% | $18.20 | $229,804 | -47.59% | ||
| 2024-07-16 | Sale | Chief Medical Officer | 5,901 0.0194% | $18.00 | $106,247 | -51.50% | ||
| 2024-07-12 | Sale | Chief Medical Officer | 3,288 0.0108% | $18.04 | $59,331 | 0.00% | ||
| 2024-07-02 | Sale | Chief Medical Officer | 37 0.0001% | $18.07 | $669 | 0.00% | ||
| 2024-07-01 | Sale | Chief Medical Officer | 875 0.0029% | $18.01 | $15,760 | 0.00% | ||
| 2024-06-24 | Sale | Chief Medical Officer | 9,260 0.0291% | $18.19 | $168,427 | -50.62% | ||
| 2024-06-12 | Sale | Chief Medical Officer | 1,086 0.0034% | $18.06 | $19,615 | -49.94% | ||
| 2024-06-11 | Sale | Chief Medical Officer | 500 0.0016% | $18.04 | $9,022 | -50.50% | ||
| 2024-06-06 | Sale | SVP, Clinical Development | 1,411 0.0045% | $18.00 | $25,398 | -48.79% | ||
| 2024-06-05 | Sale | SVP, Clinical Development | 7,245 0.0223% | $18.09 | $131,062 | -51.05% | ||
| 2024-05-17 | Sale | SVP, Chem. Mfg & Controls | 10,000 0.0306% | $13.41 | $134,100 | -31.95% | ||
| 2024-02-09 | 2.56M 10.4935% | $10.64 | $27.21M | -20.94% | ||||
| 2023-11-30 | President and CEO | 1,694 0.006% | $4.17 | $7,056 | +115.41% | |||
| 2023-06-08 | Sale | President and CEO | 2,381 0.0098% | $16.04 | $38,188 | -54.91% | ||
| 2023-06-07 | Sale | President and CEO | 8,419 0.0366% | $16.23 | $136,618 | -52.77% | ||
| 2023-06-06 | Sale | President and CEO | 18,150 0.076% | $16.18 | $293,660 | -54.30% | ||
| 2023-06-05 | Sale | President and CEO | 500 0.0022% | $16.06 | $8,028 | -52.58% | ||
| 2023-06-02 | Sale | President and CEO | 1,800 0.0075% | $16.04 | $28,863 | -54.46% |
Insider Historical Profitability
2.42%
| RA CAPITAL MANAGEMENT, L.P. | 9179273 28.161% | $2.41 | 1 | 0 | ||
| Svenstrup Niels | SVP, Chem. Mfg & Controls | 0 0% | $2.41 | 0 | 1 | |
| Mellion Michelle L | Chief Medical Officer | 0 0% | $2.41 | 0 | 12 | |
| Oxford Science Enterprises plc | 10 percent owner | 4755388 14.589% | $2.41 | 1 | 0 | |
| Shah Rajeev M. | 1302600 3.9962% | $2.41 | 1 | 0 | +7.35% | |
| Deerfield Private Design Fund V, L.P. | 476813 1.4628% | $2.41 | 1 | 0 | +7.35% | |
| KEATING LAURIE | director | 4166 0.0128% | $2.41 | 1 | 0 | <0.0001% |
| McArthur James G | President and CEO | 1694 0.0052% | $2.41 | 1 | 5 | |
| Goyal Jaya | EVP, Res. & Preclin. Dev. | 0 0% | $2.41 | 0 | 4 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| RA Capital Management, L.P. | $157.14M | 32.98 | 10.69M | +31.45% | +$37.6M | 0.16 | |
| Suvretta Capital Management, LLC | $22.36M | 4.69 | 1.52M | +212.56% | +$15.2M | 0.94 | |
| Frazier Life Sciences Management L P | $22.09M | 4.64 | 1.5M | New | +$22.09M | 1 | |
| Viking Global Investors | $21.79M | 4.57 | 1.48M | 0% | +$0 | 0.01 | |
| Perceptive Advisors | $20.73M | 4.35 | 1.41M | New | +$20.73M | 0.01 | |
| Adage Capital Partners Gp L L C | $19.6M | 4.11 | 1.33M | +21.24% | +$3.43M | 0.04 | |
| Janus Henderson | $17.23M | 3.6 | 1.17M | +18.06% | +$2.63M | 0.01 | |
| The Vanguard Group | $12.5M | 2.62 | 850,445 | +68.01% | +$5.06M | <0.0001 | |
| Laurion Capital Management LP | $12.37M | 2.6 | 841,431 | +26.62% | +$2.6M | 0.09 | |
| BlackRock | $11.49M | 2.41 | 781,437 | +8% | +$851,115.31 | <0.0001 | |
| Sofinnova | $7.4M | 1.55 | 503,624 | +2,086.06% | +$7.06M | 0.02 | |
| Fidelity Investments | $6.74M | 1.42 | 458,640 | -37.86% | -$4.11M | <0.0001 | |
| Octagon Capital Advisors LP | $5.53M | 1.16 | 376,117 | New | +$5.53M | 0.03 | |
| Geode Capital Management | $4.4M | 0.92 | 299,487 | +42.58% | +$1.31M | <0.0001 | |
| State Street | $3.54M | 0.74 | 240,982 | +11.1% | +$353,799.56 | <0.0001 | |
| Artal Group S A | $2.94M | 0.62 | 200,000 | New | +$2.94M | 0.01 | |
| Point72 Asset Management | $2.83M | 0.59 | 192,178 | New | +$2.83M | <0.01 | |
| Bridgeway Capital Management | $1.46M | 0.31 | 99,200 | 0% | +$0 | 0.02 | |
| Northern Trust | $1.36M | 0.28 | 92,195 | +23.21% | +$255,338.91 | <0.0001 | |
| Monashee Investment Management LLC | $1.26M | 0.27 | 85,886 | New | +$1.26M | 0.11 | |
| Walleye Capital | $949,826.00 | 0.2 | 64,614 | New | +$949,826.00 | <0.01 | |
| Citigroup | $596,967.00 | 0.13 | 40,610 | +2,864.23% | +$576,828.00 | <0.0001 | |
| Crestline Management Lp | $514,500.00 | 0.11 | 35,000 | New | +$514,500.00 | 0.05 | |
| Rathbone Brothers | $470,444.00 | 0.1 | 32,003 | -48.38% | -$440,999.91 | <0.01 | |
| Charles Schwab | $459,963.00 | 0.1 | 31,290 | +12.59% | +$51,450.00 | <0.0001 | |
| BNY Mellon | $452,172.00 | 0.1 | 30,760 | -2.09% | -$9,672.60 | <0.0001 | |
| Morgan Stanley | $418,685.00 | 0.09 | 28,482 | -20.7% | -$109,294.40 | <0.0001 | |
| Qube Research & Technologies | $364,354.00 | 0.08 | 24,786 | +20,051.22% | +$362,545.90 | <0.0001 | |
| Bank of America | $280,138.00 | 0.06 | 19,057 | +20.69% | +$48,024.92 | <0.0001 | |
| American Century Investments | $245,519.00 | 0.05 | 16,702 | New | +$245,519.00 | <0.0001 | |
| JPMorgan Chase | $227,586.00 | 0.05 | 15,482 | +52.64% | +$78,483.51 | <0.0001 | |
| Nuveen | $203,566.00 | 0.04 | 13,848 | 0% | +$0 | <0.0001 | |
| RhumbLine Advisers | $203,602.00 | 0.04 | 13,851 | +0.07% | +$146.99 | <0.0001 | |
| Goldman Sachs | $194,231.00 | 0.04 | 13,213 | -6.66% | -$13,862.09 | <0.0001 | |
| AllianceBernstein | $177,282.00 | 0.04 | 12,060 | 0% | +$0 | <0.0001 | |
| UBS | $147,838.00 | 0.03 | 10,057 | -7.85% | -$12,597.91 | <0.0001 | |
| Barclays | $103,000.00 | 0.02 | 7,003 | -48.97% | -$98,852.35 | <0.0001 | |
| New York State Common Retirement Fund | $95,000.00 | 0.02 | 6,480 | -0.05% | -$43.98 | <0.0001 | |
| MetLife Investment Management | $85,172.00 | 0.02 | 5,794 | New | +$85,172.00 | <0.01 | |
| American International Group | $72,809.00 | 0.02 | 4,953 | -0.86% | -$632.10 | <0.0001 | |
| Deutsche Bank | $62,166.00 | 0.01 | 4,229 | New | +$62,166.00 | <0.0001 | |
| Wells Fargo | $51,097.00 | 0.01 | 3,476 | +16.88% | +$7,379.37 | <0.0001 | |
| Ohio Strs | $52,000.00 | 0.01 | 3,600 | +89.47% | +$24,555.56 | <0.0001 | |
| Acadian Asset Management | $30,000.00 | 0.01 | 2,052 | New | +$30,000.00 | <0.0001 | |
| Ameritas Investment Partners Inc | $17,273.00 | <0.01 | 1,175 | 0% | +$0 | <0.01 | |
| CalSTRS | $14,847.00 | <0.01 | 1,010 | -38.94% | -$9,466.80 | <0.0001 | |
| Legal & General | $12,539.00 | <0.01 | 853 | 0% | +$0 | <0.0001 | |
| MetLife | $8,761.00 | <0.01 | 596 | New | +$8,761.00 | <0.0001 | |
| Amalgamated Bank | $5,000.00 | <0.01 | 337 | -72.22% | -$12,997.03 | <0.0001 | |
| Tower Research Capital | $3,954.00 | <0.01 | 269 | -84.72% | -$21,916.04 | <0.0001 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.